293 related articles for article (PubMed ID: 36283936)
1. Review of Prospective Trials Assessing the Role of Stereotactic Body Radiation Therapy for Metastasis-directed Treatment in Oligometastatic Genitourinary Cancers.
Huynh MA; Tang C; Siva S; Berlin A; Hannan R; Warner A; Koontz B; De Meeleer G; Palma D; Ost P; Tran PT
Eur Urol Oncol; 2023 Feb; 6(1):28-38. PubMed ID: 36283936
[TBL] [Abstract][Full Text] [Related]
2. Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.
Battaglia A; De Meerleer G; Tosco L; Moris L; Van den Broeck T; Devos G; Everaerts W; Joniau S
Eur Urol Oncol; 2019 Mar; 2(2):174-188. PubMed ID: 31017094
[TBL] [Abstract][Full Text] [Related]
3. Exploring All Avenues for Radiotherapy in Oligorecurrent Prostate Cancer Disease Limited to Lymph Nodes: A Systematic Review of the Role of Stereotactic Body Radiotherapy.
Ponti E; Lancia A; Ost P; Trippa F; Triggiani L; Detti B; Ingrosso G
Eur Urol Focus; 2017 Dec; 3(6):538-544. PubMed ID: 28801240
[TBL] [Abstract][Full Text] [Related]
4. A Review of Stereotactic Body Radiation Therapy in the Management of Oligometastatic Prostate Cancer.
Zhang B; Leech M
Anticancer Res; 2020 May; 40(5):2419-2428. PubMed ID: 32366385
[TBL] [Abstract][Full Text] [Related]
5. Targeting Oligometastasis with Stereotactic Ablative Radiation Therapy or Surgery in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review of Prospective Clinical Trials.
Connor MJ; Smith A; Miah S; Shah TT; Winkler M; Khoo V; Ahmed HU
Eur Urol Oncol; 2020 Oct; 3(5):582-593. PubMed ID: 32891600
[TBL] [Abstract][Full Text] [Related]
6. Role of Metastasis-Directed Therapy in Genitourinary Cancers.
Lee KN; Huynh MA
Curr Treat Options Oncol; 2024 May; 25(5):605-616. PubMed ID: 38573430
[TBL] [Abstract][Full Text] [Related]
7. Radiotherapy of oligometastatic prostate cancer: a systematic review.
Rogowski P; Roach M; Schmidt-Hegemann NS; Trapp C; von Bestenbostel R; Shi R; Buchner A; Stief C; Belka C; Li M
Radiat Oncol; 2021 Mar; 16(1):50. PubMed ID: 33750437
[TBL] [Abstract][Full Text] [Related]
8. Treatment outcomes of metastasis-directed treatment using
Hurmuz P; Onal C; Ozyigit G; Igdem S; Atalar B; Sayan H; Akgun Z; Kurt M; Ozkok HB; Selek U; Oymak E; Tilki B; Guler OC; Mustafayev TZ; Saricanbaz I; Rzazade R; Akyol F
Strahlenther Onkol; 2020 Nov; 196(11):1034-1043. PubMed ID: 32617620
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic body radiotherapy (SBRT) in metachronous oligometastatic prostate cancer: a systematic review and meta-analysis on the current prospective evidence.
Yan M; Moideen N; Bratti VF; Moraes FY
Br J Radiol; 2020 Dec; 93(1116):20200496. PubMed ID: 32822547
[TBL] [Abstract][Full Text] [Related]
10. Oligometastatic breast cancer: where are we now and where are we headed?-a narrative review.
Kent CL; McDuff SGR; Salama JK
Ann Palliat Med; 2021 May; 10(5):5954-5968. PubMed ID: 32921069
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies.
Jackson WC; Silva J; Hartman HE; Dess RT; Kishan AU; Beeler WH; Gharzai LA; Jaworski EM; Mehra R; Hearn JWD; Morgan TM; Salami SS; Cooperberg MR; Mahal BA; Soni PD; Kaffenberger S; Nguyen PL; Desai N; Feng FY; Zumsteg ZS; Spratt DE
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):778-789. PubMed ID: 30959121
[TBL] [Abstract][Full Text] [Related]
12. Local ablative stereotactic body radiotherapy for oligometastatic prostate cancer.
Niazi T; Elakshar S; Stroian G
Curr Opin Support Palliat Care; 2018 Sep; 12(3):351-358. PubMed ID: 29979320
[TBL] [Abstract][Full Text] [Related]
13. Metastasis-directed Therapy in Prostate Cancer: Prognostic Significance of the ESTRO/EORTC Classification in Oligometastatic Bone Disease.
Nicholls L; Chapman E; Khoo V; Suh YE; Tunariu N; Wang Y; van As N
Clin Oncol (R Coll Radiol); 2022 Jan; 34(1):63-69. PubMed ID: 34756755
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography.
Kneebone A; Hruby G; Ainsworth H; Byrne K; Brown C; Guo L; Guminski A; Eade T
Eur Urol Oncol; 2018 Dec; 1(6):531-537. PubMed ID: 31158100
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic body radiotherapy (SBRT) versus androgen deprivation therapy (ADT) for oligometastatic prostate cancer: protocol for a prospective randomised control clinical trial.
Zhao X; Wang T; Ye Y; Li J; Gao X; Zhang H
BMJ Open; 2022 Sep; 12(9):e051371. PubMed ID: 36180115
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of metastasis-directed therapy of bone oligometastatic prostate cancer.
Rogowski P; Trapp C; von Bestenbostel R; Schmidt-Hegemann NS; Shi R; Ilhan H; Kretschmer A; Stief C; Ganswindt U; Belka C; Li M
Radiat Oncol; 2021 Jun; 16(1):125. PubMed ID: 34193194
[TBL] [Abstract][Full Text] [Related]
17. Positron Emission Tomography and Whole-body Magnetic Resonance Imaging for Metastasis-directed Therapy in Hormone-sensitive Oligometastatic Prostate Cancer After Primary Radical Treatment: A Systematic Review.
Farolfi A; Hadaschik B; Hamdy FC; Herrmann K; Hofman MS; Murphy DG; Ost P; Padhani AR; Fanti S
Eur Urol Oncol; 2021 Oct; 4(5):714-730. PubMed ID: 33750684
[TBL] [Abstract][Full Text] [Related]
18. [Stereotactic body radiation therapy for oligometastatic prostate cancer].
Bibault JE
Bull Cancer; 2018 Jan; 105(1):120-125. PubMed ID: 29191358
[TBL] [Abstract][Full Text] [Related]
19. Stereotactic Body Radiation Therapy (SBRT) for Oligorecurrent/Oligoprogressive Mediastinal and Hilar Lymph Node Metastasis: A Systematic Review.
Cozzi S; Alì E; Bardoscia L; Najafi M; Botti A; Blandino G; Giaccherini L; Ruggieri MP; Augugliaro M; Iori F; Sardaro A; Iotti C; Ciammella P
Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681659
[TBL] [Abstract][Full Text] [Related]
20. Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracers.
Kwon DH; Shakhnazaryan N; Shui D; Hong JC; Mohamad O; de Kouchkovsky I; Borno HT; Bose R; Chou J; Desai A; Fong L; Friedlander TW; Koshkin VS; Aggarwal RR; Feng FY; Hope TA; Small EJ
Urol Oncol; 2023 Mar; 41(3):145.e7-145.e15. PubMed ID: 36435709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
